P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 11, 2025

Primary Completion Date

August 11, 2026

Study Completion Date

August 11, 2026

Conditions
Diabetic Kidney Disease
Interventions
DRUG

2HPβCD

2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.

Trial Locations (1)

78212

RECRUITING

Clinical Advancement Center, PLLC, San Antonio

All Listed Sponsors
lead

ZyVersa Therapeutics, Inc.

INDUSTRY

NCT06489340 - P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease | Biotech Hunter | Biotech Hunter